Phase I study to evaluate the safety and efficacy of rivoceranib (apatinib) and nivolumab in patients with unresectable or metastatic cancer.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.8_suppl.18
Abstract: 18 Background: Due to their immuno-modulatory effects, anti-angiogenic drugs have been clinically investigated in combination with anti-PD-1 therapies. The addition of rivoceranib (apatinib), a highly-selective VEGFR-2 tyrosine kinase inhibitor, is being evaluated in an ongoing… read more here.
Keywords: part; rivoceranib apatinib; efficacy; study ... See more keywords